Aktuella utlysningar, vecka 40, 2021
Grants Office tipsar om aktuella utlysningar.
Svenska och nordiska utlysningar
Support medical and healthcare research on kidney diseases and kidney transplants as well as information on kidney diseases. The total budget is SEK 6 million.
Closing date: 18 October 2021
Support accident and disease prevention, rehabilitation and health-promoting scientific research. The total budget is worth between SEK 1.5 – 2 million.
Closing date: 22 October 2021
Stiftelsen har till ändamål att genom stipendium samt forsknings- och reseanslag till läkare och vetenskapsmän understödja undersökningar och arbeten för bekämpande av de svåraste folksjukdomarna. Vid ansökningsomgången 2021 kommer anslag företrädesvis att ges till yngre forskare inom 2 år efter disputation.
Closing date: 31 October 2021
The European Health Data and Evidence Network invites applications for its data partner call. This enables data partners in Europe to map their health data to the Observational Medical Outcomes Partnership common data model. The aim of the project is to standardise more than 100 million patient records across Europe from different geographic areas and data sources.
Grants are worth up to €100,000 for each data partner.
Closing date: 13 November 2021 (Forecast) Based on past experience, we forecast the deadline to be around November 2021. This call is repeated 2 times a year.
This supports research on the link between diet, nutrition, body composition, physical activity, and cancer prevention and survival. These research areas may be approached by either identifying the mechanisms that underpin the effects of diet, nutrition and physical activity on cancer, or by addressing the risk factors that influence individual susceptibility to cancer development, progression and survival, contributing to the evidence on variability between people in outcomes. Two types of grants are available:
• investigator-initiated grants, worth a maximum of £350,000 for up to four years
• seed grants worth up to £60,000 over two years.
Grants are awarded to principal investigators based at institutions in any country outside the Americas. International collaborations and applications from low- and middle-income countries are particularly encouraged.
Closing date: 16 November 2021 (Applications due by 16 November 2021; full applications due by 25 March 2022. This call is repeated once a year.)
These support transnational scientific collaboration and advanced training in techniques or methodologies.
Applicants must be under the age of 35 and hold at least a master’s degree. An extension of the age limit of up to 18 months may be granted for parental leave and civil or military service. Applicants must be members of a society affiliated with EFIS, with an exception made for applicants from European countries without a national society. The proposed stay must be conducted at a European institution.
The fellowship is worth €1,750 per month for up to three months, and includes travel reimbursement of up to €500.
Closing date: 13 November 2021
These support clinical or fundamental research projects focused on human gut microbiota related to health and disease. For the current round, projects will have to focus on the clinical effects of different microbiota interventions, such as antibiotics, FMT, diet and probiotics, in patients with autism.
Physicians, PhDs and doctors of pharmacy working in subject areas, such as gastroenterology, paediatrics, microbiology, infectious diseases and internal medicine and based anywhere in the world, may apply.
The grant is worth €200,000 over one to three years.
Closing date: 30 November 2021
This aims to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes. Areas of research emphasis may include:
•mechanisms to induce browning of adipose tissue;
•new targets for improving skeletal muscle or adipose tissue insulin resistance;
•bile acid biology as it relates to metabolic disease, including actions relating to glucose metabolism, lipid metabolism, energy balance and related diseases;
•lipid metabolism as it relates to insulin action;
•mechanisms of glucose-dependent insulin and glucagon secretion.
Single non-profit institutions or groups of such institutions from Europe and associated countries may apply. Grants are worth up to €100,000 each for projects lasting one year or longer.
Closing date: 1 December 2021
Federal Funding agencies
Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed), NIH
This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs.
Closing date: February 04, 2022. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-22-037
The purpose of this FOA is to solicit Research Project Grant (R01) applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of the stigmas at individual levels.
Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or care givers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
One or more investigators from an academic or research institution in the U.S. and one or more investigators from an academic or research institution in an LMIC are strongly encouraged to collaborate as key personnel on this application.
Closing date: December 20, 2021 & December 20, 2022. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-21-344
This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.
Closing date: November 2, 2021; August 1, 2022; March 13, 2023. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-HG-20-037 (R21); RFA-HG-20-036 (R01).
The Society is pleased to offer a funding opportunity for investigator-initiated proposals to support research focused on addressing research questions highlighted in the Pathways to Cures Roadmap.
The Roadmap includes three Pathways: STOPPING MS disease activity, RESTORING function by reversing damage and symptoms, and ENDING MS by preventing new cases. Applicants must clearly state the relevance of their proposals to at least one of the research questions outlined in the Roadmap. Refer to the Roadmap for more clarity, and feel free to reach out to Research staff listed below to discuss relevant topics.
The Society supports all types of research including laboratory models, human studies, population-based approaches, and data-intensive investigations that leverage both researcher and patient-reported outcomes. We value studies that:
- promote synergies between researchers in diverse disciplines;
- adhere to principles of sharing data and resources;
- focus on underserved and understudied ethnic and racial MS populations (Please consult this toolkit for strategies regarding Minority Engagement in MS Research).
A total expense of up to $200,000 USD per year (including indirect costs) for up to 3 years of support will be provided and must be justified based on the aims of the proposal.
Closing date: November 10, 2021 (Pre-applications); November 17, 2021 (Full proposals).
Research Grant, Guillain-Barre Syndrome/Chronic Inflammatory Demyelinating Polyneuropathy Foundation International (GBS/CIDP), US
GBS/CIDP Foundation International invites letters of intent for its research grants. These support researchers who are committed to learning more about Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy and variants.
The foundation encourages all interested parties to submit applications, including international applicants.
Multiple grants worth up to USD 60,000 over one year are available.
Closing date: Letters of Intent are due via website portal November 1, Full Application due (Invitation only) December 1, Announcement of Awards January 15.
JDRF invites applications for its international diabetes psychology fellowship programme. This supports an early-career fellowship with a mentor who can provide a training environment conducive to a career in type 1 diabetes-relevant psychosocial research. The fellowship programme encourages a combination of clinical diabetes care and diabetes research.
Applicants must have documented research experience, a career interest in type 1 diabetes specialised psychology and must have completed a PsyD, a PhD or an MD no more than five years prior.
Fellowships are worth up to USD 65,000 per year and may last up to two years.
Closing date: November 9, 2021; Applicants Notified of JDRF’s Funding Decisions: 21 February, 2022; Earliest Start Date: April 1, 2022.